novo Thank believe dedicated be first also we protein lead program completed public towards enter to being an a development. Throughout novo Therapeutics. you, following operations Aquinox started a program. and follow-on financing and good transition novel from runway, our as platform and Julie, enable January, our was in have therapeutic research build technology in diligently de private We our entity this a and a ended experienced team became to the public independent year built clinical time NL-XXX, clinical this efforts. focused our year will for exciting and a of We've merger everyone. with a a de company. August, XXXX transformational and with to the at team Neoleukin Pharmaceuticals afternoon, We on fully our to Neoleukin, extend advancement testing advancing immuno-oncology
spend product made some look to overview our and reviewing what lead progress like we've the to date forward time ahead. we to to year technology highlighting an providing the I'd candidate, and briefly in today of have
Institute our entirely us de platform therapeutics. licensed for a leadership under inventors or University University world's leaders one David computational is novo protein. the at The create to This cofound Design allows to algorithms proprietary Protein Neoleukin. from The the technology on that new of the technology First, protein Washington of set of platform. of left in Baker, the the Washington Neoleukin was of
biologics, the shift the paradigm rational approach enabling highly protein design specific new of a Our represents of discovery in therapeutics.
Our lead to IL-X been or demonstrated with IL-X monotherapy cancer-fighting response IL-XX X% approved XX%, extensively cancer treatment and a is NL-XXX responses. receptors cell X% the to is cytokine, and of melanoma, agonist expand potent novo which rates complete both NK and cells. and T-cells the studied of asset for natural effector approximately renal has Interleukin-X de a of and
high setting not toxicities sufficient antitumor administration low-dose and dose has that drug IL-X IL-X require does hospital activity. in However, have significant a
exist based that addressed as using high of is problem Neoleukin, this leak we the protein, well of is sequence T side nature vascular and the in syndrome and novo on technology limitations to and new consisting de of components to have binding and doses. by can high on these which signaling these to regulatory chain consisting be underlying beta to alpha receptor, cells, biodistribution native subunits. does IL-X. The as believed doses, immunosuppression cause effects, cells severe design as not low biological at as alpha a cells well preferential native affinity biology gamma such the as our one IL-X an At endothelial localization not chain Expression the trimeric of at of the drives entirely
Our and highly as likely has algorithms absence de affinity that make in immune also and to them redesigned, been hydrophilic and of foreign alpha be the less enabling binding stable, binding system. compact properties high protein computational novo Furthermore, by activation create our has proteins, subunit the domain no the alpha chain. recognized
development effect de X interest is efficiently NL-XXX more Difficulty] the of next-generation and high novo beta the agonists Because IL-X that of more to gamma agonist activity has affinity IL-X should is immune a in our pure IL-XX cells of or share a potent respond of signaling either protein on for arms and cells, gamma these chains. lot activate and that both on [Technical beta IL-XX T-cells, There's and NK activator the of immunotherapy. system. a normally cytokines cancer has IL-XX, related
a be starting to stable and retain residual de IL-X be engineered potent subunit. [Technical alpha NL-XXX is alpha protein IL-XX others engineered, or with such Difficulty] with as In are to the less and However, a believe native that likely molecules We designed no variants. contrast, novo less producing are highly expected to potent, binding. binding
NL-XXX, GLP Let transferred target lead with to XXXX. and toxicities preclinical progress no which multidose nonhuman and CMC the process manufacturing our conducted downstream me to organization, asset produced studies meet and GMP non-GLP now unexpected rats for have batches end testing. purification to to requirements IND We've toxicology successfully on turn of submission modified in remains our with support a our observed. contract before the primates multiple We've
undergoing and support testing PK potency release development well to submission Assays to track on IND and immunogenicity and clinical activities. and as as are validation, support are
models of studying a combinations. Additionally, we array to syngeneic more learn continue strategies activity about various antitumor and NL-XXX's tumor dosing and evaluating by wide
undergone reported has to expect X we extension, support the dosing clinical systemic patients. we every to which molecule to have weeks modification enable X in As previously, half-life
solid in will dose will patient by more monotherapy to This the tumors monotherapy of trial schedule. clinical populations. first-in-human cohort advanced estimate Our followed to focus to intravenous and determine safety antitumor uniform administration activity recommended expansions patients and be with indication-specific on
and the research Turning to other programs pipeline. in
design. areas protein novo X focused of de are scientists Our on
building to First, enables that us computational underlie and sophistication know-how capabilities experience the we're of increase the our algorithms that and platform.
what evolve and to clinical technology we works our that about preclinical more as learn continue studies. in expect will best We
to cytokine potent administration inhibitors that PH, the Second, receptors on proteolytic treatment ability conditionally de withstand proteins further opportunity high that of to activated micro we're autoimmune widening of engage The mimetics novo for low will inhibitors to and very therapeutic avoid that tumor in systemic third, One exciting index hyper de protein cytokine and novo And only stable create inflammation using the is environments, potent we're working the building of immunotherapies. environment. allow enable harsh including receptor design target can local temperature diseases. may enzymes design toxicities.
The last without half progress be has year we've the Since research, team. made in employees, launched protein in group. operations than our would including past immunology significantly possible XX scientists expanded our in team more headquarters. approximately Neoleukin computational and we January, great scientists, We are Seattle have the not currently a biology
stay especially Seattle-based stayed in In transition recently He to the senior thank addition, Chief contributions becoming Vancouver, will we've our Neoleukin Kam a leadership Pharmaceuticals, Ho, on After British our with finance a of the an team company. the will as His public to Kam based Financial moment and through like to Kam next strategic who to take Robert group a during hiring very and on his week. take Officer, announced Alam from I'd the strategic follow-on Aquinox hired have adviser Columbia. with effective interim of offering. end and a valuable, merger basis help been May. over
Kam over like that, turn I'd now to call And to to the XXXX Kam? financials. with our year-end discuss
